A professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business.
In a discussion on global trade disruption, Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, explains why pharmaceutical manufacturers must move beyond broad assumptions about tariffs and instead assess trade risk at the individual product level.
Pharma’s push into direct-to-patient sales is reshaping the front end of drug distribution, but wholesalers like Cencora, McKesson, and Cardinal Health remain indispensable as the backbone of the industry’s regulated, specialty, and logistics infrastructure.
Ways to address limitations while also enhancing the decision-making process.
This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.
With great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.
